SAN DIEGO, Feb. 10, 2017 /PRNewswire/ -- Pfenex Inc.
(NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in
the development of biosimilar therapeutics, including high-value
and difficult to manufacture proteins, today announced that it will
participate in the BIO 2017 CEO & Investor Conference in
New York City. Pfenex's Interim
CEO, Patrick Lucy, is scheduled to
participate in the panel discussion "Living with Biosimilars:
Strategy Formulation and Lessons from Other Markets" on
Tuesday, February 14, 2017, at
9:00 AM EST.
About Pfenex Inc.
Pfenex Inc. is a clinical-stage
biotechnology company engaged in the development of biosimilar
therapeutics and high-value and difficult to manufacture proteins.
The Company's lead product candidate is PF582, a biosimilar
candidate to Lucentis (ranibizumab), for the potential treatment of
patients with retinal diseases. Pfenex has leveraged
its Pfēnex Expression
Technology® platform to build a pipeline of
product candidates and preclinical products under development
including other biosimilars, as well as vaccines, therapeutic
equivalents to reference listed drug products, and next generation
biologics.
Pfenex investors and others should note that we announce
material information to the public about the Company through a
variety of means, including our website (http://www.pfenex.com/),
our investor relations website (http://pfenex.investorroom.com/),
press releases, SEC filings, public conference calls, corporate
Twitter account (https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with our disclosure
obligations under Regulation FD. We encourage our investors and
others to monitor and review the information we make public in
these locations as such information could be deemed to be material
information. Please note that this list may be updated from time to
time.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pfenex-inc-to-participate-in-panel-discussion-at-2017-bio-ceo--investor-conference-300405425.html
SOURCE Pfenex Inc.